151 related articles for article (PubMed ID: 23607649)
1. Compritol®888 ATO a lipid excipient for sustained release of highly water soluble active: formulation, scale-up and IVIVC study.
Patere SN; Desai NS; Jain AS; Kadam PP; Thatte UM; Gogtay N; Kapadia CJ; Farah N; Nagarsenker MS
Curr Drug Deliv; 2013 Oct; 10(5):548-56. PubMed ID: 23607649
[TBL] [Abstract][Full Text] [Related]
2. Influence of Formulation Factors and Compression Force on Release Profile of Sustained Release Metoprolol Tablets using Compritol(®) 888ATO as Lipid Excipient.
Patere SN; Kapadia CJ; Nagarsenker MS
Indian J Pharm Sci; 2015; 77(5):620-5. PubMed ID: 26798179
[TBL] [Abstract][Full Text] [Related]
3. Development and evaluation of sustained-release Compritol® 888 ATO matrix mini-tablets.
Roberts M; Vellucci D; Mostafa S; Miolane C; Marchaud D
Drug Dev Ind Pharm; 2012 Sep; 38(9):1068-76. PubMed ID: 22149472
[TBL] [Abstract][Full Text] [Related]
4. Optimizing a wet granulation process to obtain high-dose sustained-release tablets with Compritol 888 ATO.
Rosiaux Y; Girard JM; Desvignes F; Miolane C; Marchaud D
Drug Dev Ind Pharm; 2015; 41(10):1738-44. PubMed ID: 25652358
[TBL] [Abstract][Full Text] [Related]
5. Melt granulation and heat treatment for wax matrix-controlled drug release.
Zhang YE; Schwartz JB
Drug Dev Ind Pharm; 2003 Feb; 29(2):131-8. PubMed ID: 12648009
[TBL] [Abstract][Full Text] [Related]
6. Effect of formulation and process variables on lipid based sustained release tablets via continuous twin screw granulation: A comparative study.
Kallakunta VR; Tiwari R; Sarabu S; Bandari S; Repka MA
Eur J Pharm Sci; 2018 Aug; 121():126-138. PubMed ID: 29772273
[TBL] [Abstract][Full Text] [Related]
7. Preparation and characterization of Compritol 888 ATO matrix tablets for the sustained release of diclofenac sodium.
Roberts M; Pulcini L; Mostafa S; Cuppok-Rosiaux Y; Marchaud D
Pharm Dev Technol; 2015 Jun; 20(4):507-12. PubMed ID: 24354893
[TBL] [Abstract][Full Text] [Related]
8. Compritol 888 ATO: a multifunctional lipid excipient in drug delivery systems and nanopharmaceuticals.
Aburahma MH; Badr-Eldin SM
Expert Opin Drug Deliv; 2014 Dec; 11(12):1865-83. PubMed ID: 25152197
[TBL] [Abstract][Full Text] [Related]
9. Development and internal validation of an in vitro-in vivo correlation for a hydrophilic metoprolol tartrate extended release tablet formulation.
Eddington ND; Marroum P; Uppoor R; Hussain A; Augsburger L
Pharm Res; 1998 Mar; 15(3):466-73. PubMed ID: 9563079
[TBL] [Abstract][Full Text] [Related]
10. Core-in-cup tablet design of metoprolol succinate and its evaluation for controlled release.
Nagaraju R; Meera DS; Kaza R; Arvind VV; Venkateswarlu V
Curr Drug Discov Technol; 2009 Dec; 6(4):299-305. PubMed ID: 20025598
[TBL] [Abstract][Full Text] [Related]
11. Influence of stereoselective pharmacokinetics in the development and predictability of an IVIVC for the enantiomers of metoprolol tartrate.
Sirisuth N; Eddington ND
Pharm Res; 2000 Aug; 17(8):1019-25. PubMed ID: 11028951
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of in vitro release rate and in vivo absorption characteristics of four metoprolol tartrate immediate-release tablet formulations.
Rekhi GS; Eddington ND; Fossler MJ; Schwartz P; Lesko LJ; Augsburger LL
Pharm Dev Technol; 1997 Feb; 2(1):11-24. PubMed ID: 9552427
[TBL] [Abstract][Full Text] [Related]
13. Comparative study on the different techniques for the preparation of sustained-release hydrophobic matrices of a highly water-soluble drug.
Abd El-Halim SM; Amin MM; El-Gazayerly ON; Abd El-Gawad NA
Drug Discov Ther; 2010 Dec; 4(6):484-92. PubMed ID: 22491314
[TBL] [Abstract][Full Text] [Related]
14. Exploring the possible relationship between the drug release of Compritol®-containing tablets and its polymorph forms using micro X-ray diffraction.
Jannin V; Rosiaux Y; Doucet J
J Control Release; 2015 Jan; 197():158-64. PubMed ID: 25445699
[TBL] [Abstract][Full Text] [Related]
15. Effects of formulation and process variables on the release of a weakly basic drug from single unit extended release formulations.
Kranz H; Wagner T
Eur J Pharm Biopharm; 2006 Jan; 62(1):70-6. PubMed ID: 16154330
[TBL] [Abstract][Full Text] [Related]
16. Innovation of novel sustained release compression-coated tablets for lornoxicam: formulation and in vitro investigations.
Hamza Yel-S; Aburahma MH
Drug Dev Ind Pharm; 2010 Mar; 36(3):337-49. PubMed ID: 19722915
[TBL] [Abstract][Full Text] [Related]
17. Formulation and In Vitro and In Vivo Evaluation of Lipid-Based Terbutaline Sulphate Bi-layer Tablets for Once-Daily Administration.
Hashem FM; Nasr M; Fathy G; Ismail A
AAPS PharmSciTech; 2016 Jun; 17(3):727-34. PubMed ID: 26335420
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of "external" predictability of an in vitro-in vivo correlation for an extended-release formulation containing metoprolol tartrate.
Mahayni H; Rekhi GS; Uppoor RS; Marroum P; Hussain AS; Augsburger LL; Eddington ND
J Pharm Sci; 2000 Oct; 89(10):1354-61. PubMed ID: 10980510
[TBL] [Abstract][Full Text] [Related]
19. Preparation of Sustained Release Tablet with Minimized Usage of Glyceryl Behenate Using Post-Heating Method.
Kang C; Lee JH; Kim DW; Lee BJ; Park JB
AAPS PharmSciTech; 2018 Oct; 19(7):3067-3075. PubMed ID: 30094721
[TBL] [Abstract][Full Text] [Related]
20. Use of natural gums and cellulose derivatives in production of sustained release metoprolol tablets.
Varshosaz J; Tavakoli N; Eram SA
Drug Deliv; 2006; 13(2):113-9. PubMed ID: 16423799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
